-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

ASH Poster Walk on Immunotherapies: A Walk Down Immunotherapy Lane: Watch Out for the CARs: Live Q&A

PhD Trainee
Program: ASH Poster Walks
Thursday, December 10, 2020: 7:00 AM-8:00 AM
Moderator:
Disclosures:
No relevant conflicts of interest to declare.
Panelists:
Rodrigo T. Calado, MD, PhD, University of Sao Paulo , Antonio Risitano, MD, PhD, University of Naples , Steven Z. Pavletic, MD, MS, Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Noelle V. Frey, MD, MS, Hospital of the University of Pennsylvania , Loretta J. Nastoupil, MD, The University of Texas MD Anderson Cancer Center , Jie Wang, MD, MS, Duke University , Jordan Gauthier, MD, Fred Hutchinson Cancer Research Center , Viktoria Blumenberg, MD, Department of Medicine III, University Hospital, LMU Munich , Michael B. Jordan, MD, Division of Immunobiology, Cincinnati Children's Hospital Medical Center , Federico Simonetta, MD, PhD, Stanford University , Peter Hillmen, MBChB, FRCP, FRCPath, PhD, St. James's University Hospital and Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center
Disclosures:
No relevant conflicts of interest to declare.
The following abstracts will be featured during this session:

A Novel Approach for Treatment of T-Cell Malignancies: Targeting T-Cell Receptor Vβ Families, Jie Wang

High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics, Jordan Gauthier

Antibiotic Therapy and Low Gut Microbiome Diversity Is Associated with Decreased Response and High Toxicity in BCP-ALL and DLBCL Patients after Treatment with CD19. CAR T-Cells, Viktoria Blumenberg

Sensitivity Analysis of Overall Response Rate (ORR) with Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis (HLH), Michael Jordan

Molecular Imaging of Chimeric Antigen Receptor T Cells By ICOS-Immunopet, Federico Simonetta

Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria, Peter Hillmen

See more of: ASH Poster Walks